Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9
出版年份 2011 全文链接
标题
Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9
作者
关键词
-
出版物
JOURNAL OF LIPID RESEARCH
Volume 52, Issue 4, Pages 679-687
出版商
American Society for Biochemistry & Molecular Biology (ASBMB)
发表日期
2011-01-25
DOI
10.1194/jlr.m013664
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: a randomized trial
- (2010) K. Berneis et al. EUROPEAN HEART JOURNAL
- A Proprotein Convertase Subtilisin-like/Kexin Type 9 (PCSK9) C-terminal Domain Antibody Antigen-binding Fragment Inhibits PCSK9 Internalization and Restores Low Density Lipoprotein Uptake
- (2010) Yan G. Ni et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo
- (2010) Yan G. Ni et al. JOURNAL OF LIPID RESEARCH
- Strong induction of PCSK9 gene expression through HNF1α and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters
- (2010) Bin Dong et al. JOURNAL OF LIPID RESEARCH
- High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol
- (2010) Greg Welder et al. JOURNAL OF LIPID RESEARCH
- The siRNA sequence and guide strand overhangs are determinants of in vivo duration of silencing
- (2010) Walter R. Strapps et al. NUCLEIC ACIDS RESEARCH
- A Locked Nucleic Acid Antisense Oligonucleotide (LNA) Silences PCSK9 and Enhances LDLR Expression In Vitro and In Vivo
- (2010) Nidhi Gupta et al. PLoS One
- Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor
- (2009) Christopher J. Duff et al. BIOCHEMICAL JOURNAL
- A new method for measurement of total plasma PCSK9: clinical applications
- (2009) Geneviève Dubuc et al. JOURNAL OF LIPID RESEARCH
- Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men
- (2009) Thomas Sudhop et al. JOURNAL OF LIPID RESEARCH
- A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates
- (2009) J. C. Y. Chan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- An assessment of the carcinogenic potential of ezetimibe using nonclinical data in a weight-of-evidence approach
- (2009) M. Halleck et al. TOXICOLOGY
- PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide
- (2008) LiXin Shan et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Plasma PCSK9 preferentially reduces liver LDL receptors in mice
- (2008) Aldo Grefhorst et al. JOURNAL OF LIPID RESEARCH
- Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
- (2008) John J.P. Kastelein et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular basis for LDL receptor recognition by PCSK9
- (2008) H. J. Kwon et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates
- (2008) M. Frank-Kamenetsky et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started